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OBJECTIVE—The activation of -cell genes, particularly of
those encoding preproinsulin, requires an appropriate euchroma-
tin (or “open”) DNA template characterized by hypermethylation
of Lys4 of histone H3. We hypothesized that this modiﬁcation is
maintained in islet -cells by the action of the histone methyl-
transferase Set7/9.
RESEARCH DESIGN AND METHODS—To identify the role
of Set7/9, we characterized its expression pattern and gene
regulation and studied its function using RNA interference in
both cell lines and primary mouse islets.
RESULTS—Within the pancreas, Set7/9 protein shows striking
speciﬁcity for islet cells, including - and -cells, as well as
occasional cells within ducts. Consistent with these ﬁndings, the
Set7/9 gene promoter contained an islet-speciﬁc enhancer lo-
cated between 5,768 and 6,030 base pairs (relative to the
transcriptional start site) that exhibited Pdx1-responsive activa-
tion in -cells. To study Set7/9 function, we depleted insulinoma
cells and primary mouse islets of Set7/9 protein using siRNA.
Following siRNA treatment, we observed striking repression of
genes involved in glucose-stimulated insulin secretion, including
Ins1/2, Glut2, and MafA. These changes in transcription were
accompanied by loss of dimethylated H3 Lys4 and RNA polymer-
ase II recruitment, particularly at the Ins1/2 and Glut2 genes.
Consistent with these data, depletion of Set7/9 in islets led to
defects in glucose-stimulated Ca
2 mobilization and insulin
secretion.
CONCLUSIONS—We conclude that Set7/9 is required for nor-
mal -cell function, likely through the maintenance of euchro-
matin structure at genes necessary for glucose-stimulated insulin
secretion. Diabetes 58:185–193, 2009
I
t is becoming increasingly clear that the pathogene-
sis of type 1 and type 2 diabetes involves progressive
dysfunction at the level of the islet -cell (1). Thus,
the most effective therapeutic approaches to diabe-
tes should include efforts to address -cell dysfunction,
and further research into the mechanisms underlying
-cell gene transcription will be paramount in these ef-
forts. In recent years, a model has been emerging that
emphasizes the role of -cell–speciﬁc transcription factors
such as Pdx1, Nkx6.1, NeuroD1, and Maf factors in the
expression and regulation of genes crucial to the develop-
ment and function of -cells (recent reviews in 2–4).
However, transduction of a variety of non–-cell types
with these and other transcription factors has yielded
limited success in activating -cell genes and suggests that
this model of -cell gene activation requires further reﬁne-
ment. In this regard, chromatin structure is becoming
recognized as a crucial factor in modulating eukaryotic
gene expression. Covalent modiﬁcations of the histone
proteins H2A, H2B, H3, and H4 that make up the funda-
mental unit of chromatin have been shown to directly or
indirectly lead to the formation of euchromatin (“open,” or
active, chromatin) or heterochromatin (“closed,” or inac-
tive, chromatin) (5–7). These modiﬁcations include meth-
ylation, acetylation, phosphorylation, and ubiquitination of
speciﬁc amino acid residues in the NH2-terminal histone
tails. The roles of chromatin and histone modiﬁcations in
-cell gene transcription have received attention only in
recent years.
Our laboratory and others have been particularly inter-
ested in the role of methylation of Lys4 of H3 in the
activation of -cell genes. For example, recent studies
have demonstrated that H3-Lys4 methylation at the control
region of the genes encoding cell cycle inhibitors p27Kip1
and p18Inc4c is crucial in their activation and subsequent
suppression of -cell tumorigenesis (8). Maintenance of
this methylation state appears to involve a complex con-
taining the protein menin and members of the SET meth-
yltransferase family, the mixed lineage leukemia proteins
(9). Similarly, our laboratory has demonstrated that mono-
and dimethylation of H3 Lys4 is enriched in the control
region of the gene encoding preproinsulin (Ins1/2) and
that the maintenance of dimethylated H3 Lys4 by a tran-
scriptional protein complex involving Pdx1 is crucial to
the ongoing activation of this gene in -cell lines (10,11).
Because Pdx1 contains no methyltransferase activity, we
proposed that another member of the SET protein family,
Set7/9, may be recruited to a complex with Pdx1 to
mediate H3 methylation at the Ins1/2 gene (10). Set7/9 is a
366 amino acid enzyme containing a COOH-terminal SET
domain that harbors methyltransferase activity (12,13).
This methyltransferase activity is speciﬁc not only for H3
Lys4 but also for particular Lys residues in proteins such
as p53, TAF10, and the estrogen receptor (14–19). How-
ever, consistent with a direct role in gene transcription in
the islet, our prior studies using chromatin-reconstituted
reporters in vitro showed that the interaction of Pdx1 with
Set7/9 leads to synergistic gene activation in a methyl-
transferase-dependent manner (11). These data have led
us to hypothesize that Set7/9 may represent a novel
chromatin-modifying protein that functions in part
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DIABETES, VOL. 58, JANUARY 2009 185through its recruitment to target genes by cell-speciﬁc
transcription factors such as Pdx1. In this study, we show
that Set7/9 is strongly enriched in islets relative to other
pancreatic cell types and that it is important in the
maintenance of transcription and chromatin structure at
genes necessary for glucose-stimulated insulin secretion in
primary islets. Taken together, our data identify Set7/9 as
a novel enzymatic cofactor necessary for maintenance of
islet gene transcription.
RESEARCH DESIGN AND METHODS
Antibodies and cells. Polyclonal antibody against monomethyl–H3 Lys4 was
from Abcam, and antibodies against dimethylated H3 Lys4, Pdx1, and Set7/9
were from Millipore; anti-RNA polymerase II COOH-terminal domain was
from Covance; anti-actin, anti-glucagon, and anti-insulin were from Santa Cruz
Biotechnology. TC3 cells, INS-1 (832/13), TC1.6, and NIH3T3 were main-
tained as previously described (20,21). Islets were isolated from C57BL/6J
mice following collagenase digestion of pancreatic tissue as previously
described (22). Techniques and protocols were approved by the Indiana
University Institutional Animal Care and Use Committee.
Real-time RT-PCR. Real time RT-PCR was performed using forward and
reverse primers to amplify insulin premRNA (5-GGGGAGCGTGGCTTCT-
TCTA-3 and 5 GGGGACAGAATTCAGTGGCA-3)o rActb (5-AGGTCATCAC-
TATTGGCAACGA-3 and 5-CACTTCATGATGGAATTGAATGTAGTT-3)a s
previously described in detail (23). Primers for Setd7, Slc2a2, Gck, Nkx6–1,
NeuroD1, Foxo1, Pax6, Iapp, Mafa, Ipf1, Kcnj11, Abcc8, and Foxa2 were
obtained from Qiagen (Quantitech primer kit catalog nos. QT00139727,
QT00103537, QT00140007, QT00143318, QT00251265, QT00116186, QT01052786,
QT00101052, QT01037638, QT00102235, QT00305319, QT01042300, and
QT00242809, respectively). PCR products were subcloned and sequenced to
verify ampliﬁcation of the correct gene product. All values are normalized to Actb
mRNA levels.
Immunoblot Assays. Whole-cell extracts were prepared from homogenized
tissues, 50 islets, or 1  10
6 TC3 cells by lysis in a buffer containing sodium
dodecyl sulfate, and 5 g extract was resolved by electrophoresis on a 12%
SDS-polyacrylamide gel followed by immunoblot with anti-Set7/9 or anti-actin
antisera. Immunoblots were visualized using the ECL-Plus system (Amersham).
Chromatin immunoprecipitation assays. Chromatin immunoprecipitation
(ChIP) assays were performed as previously described (20). Brieﬂy, 10
7 TC3
cells or 300 mouse islets were ﬁxed in 1% formaldehyde to cross-link proteins to
DNA, and cells were lysed and chromatin sheared to 400–600 base pairs (bp) by
sonication. Antibodies were used to subsequently immunoprecipitate the protein
of interest and then recovery of coimmunoprecipitated DNA fragments was
assessed using SYBR green–based quantitative real-time PCR. Data are expressed
as the percent recovery of coimmunoprecipitated DNA relative to input DNA
(before immunoprecipitation). Primers used for ampliﬁcation were as follows: for
the Ins1/2 promoter, 5-TACCTTGCTGCCTGAGTTCTGC-3 forward and 5-
GCATTTTCCACATCATTCCCC-3 reverse; the Ins1/2 coding region, 5-TGGCT-
TCTTCTACACACCCAAG-3 forward and 5-ACAATGCCACGCTTCTGCC-3
reverse; the Slc2a2 promoter, 5-ATCTGGCTCCGCACTCTCATCTTG-3 forward
and 5- CCCTGTGACTTTTCTGTGTCTTAGG-3 reverse; the Pdx1 promoter,
5-AGCCTGGACTACATCTTGAGTTGC-3 forward and 5-TTACAAAACCGCTC-
CCAATGAG-3 reverse; and the Setd7 promoter, 5- TCCTGTTGCCATCAT-
CAAAA-3 forward and 5-ACATGAAGGCACCACATGAA-3 reverse.
Immunohistochemistry. Mouse pancreata were ﬁxed by cardiac perfusion
with 4% paraformaldehyde, parafﬁn embedded, and sectioned at 5-m inter-
vals. Human pancreatic samples were obtained from the University of Virginia
Human Islet Transplant Program, ﬁxed for2hi n4 %paraformaldehyde, and
processed similarly to mouse pancreata. Immunohistochemical analysis of
insulin (anti-insulin, 1:500 dilution), Pdx1 (anti-Pdx1, 1:2,000 dilution), gluca-
gon (anti-glucagon, 1:500 dilution), and Set7/9 (anti-Set7/9, 1:50), was per-
formed as previously described (11). For immunoﬂuorescence, secondary
antibodies were goat anti-rabbit–conjugated to Alexa Fluor 555 and donkey
anti-mouse–conjugated to Alexa Fluor 488 (Molecular Probes). Images were
acquired using a Zeiss Z1 microscope equipped with Apotome optical section-
ing hardware.
Transfection of cell lines with siRNA. siRNAs against Set7/9 or a scram-
bled control were mixed with Reagent V (Amaxa, Inc.) and transfected into
3  10
6 TC3 mouse insulinoma cells using an Amaxa Nucleofector (program
D-23) according to the manufacturer’s protocol. Cells were then plated in a
six-well dish containing culture medium for 72 h and then harvested for
protein, total RNA, or ChIP analysis. siRNA sequences used were as follows:
siSet97, 5-GGUUUAUGUUGCCGACUCTT-3; siSet98, 5-GGUAGCAGUUG-
GACCUAAUTT-3; and a control siRNA (siControl), 5-AAAGUCGACCUU-
CAGUAAGUU-3.
In vivo delivery of siRNA. Stabilized siRNAs were obtained from Dharma-
con and diluted in 0.9% saline. Eight-week-old male C57BL/6J mice were
injected intraperitoneally with 1.6 mg/kg mouse wt siRNA daily for 4 days.
Islets were then harvested, handpicked and allowed to recover overnight and
then subjected to glucose-stimulated insulin secretion (GSIS)/glucose-stimu-
lated Ca
2 mobilization (GSCa) studies (see below), protein isolation, or RNA
isolation. siRNA sequences used were as follows: siSet1, 5-CGGACAGAUUU-
GAGGGCAAUU-3; siSet2, 5-GGGUUUAUGUUGCCGACUCUU-3; and siCon-
trol, 5-AAAGUCGACCUUCAGUAAGUU-3.
GSIS and GSCa studies. For GSIS studies, 50 islets per condition were
incubated in Krebs-Ringer HEPES buffered solution for1ha t37°C and then
placed in Krebs-Ringer HEPES buffered solution containing 3 or 11 mmol/l
glucose for 1 h. Insulin released into the medium was assayed using a two-site
immunospeciﬁc ELISA (Alpco Diagnostics). GSCa in mouse islets was mea-
sured using the ratiometric Ca
2 indicator Fura-2AM as described previously
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FIG. 1. Tissue expression pattern of Set7/9. Mouse tissues were harvested
for either RNA or protein, and mouse pancreatic tissue was harvested for
immunohistochemistry. A: Quantitative real-time RT-PCR for the gene
encoding Set7/9 in the mouse tissues indicated. Data shown are corrected
for Actb mRNA levels and normalized to the levels seen in muscle. B:
Immunoblot analysis of Set7/9 protein and actin proteins from mouse
tissues indicated. C and D: Mouse pancreas was harvested, ﬁxed, and
stained using primary antibodies to Set7/9 and secondary horseradish
peroxidase–linked anti-rabbit antibodies. Representative images of a
pancreas at 10 (C) and 40 (D) magniﬁcations are shown. E–M:
Dual-immunoﬂuorescence staining of representative islets from pancre-
atic sections showing localization of Set7/9 (E, H, and K) with insulin (F
and G), glucagon (I and J), or Pdx1 (L and M). (Please see http://
dx.doi.org/10.2337/db08-1150 for a high-quality digital representation of
this ﬁgure.)
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(340/380 nm ﬂuorescence) in 11 mmol/l vs. 3 mmol/l glucose. Data were
analyzed with IP Lab software, version 4.0 (Scanalytics).
Cloning of the Setd7 promoter. A genomic clone containing 8,000 bp of
the Setd7 gene was used as a template in PCR reactions to generate various
fragments of the Setd7 gene, which were then subcloned upstream of the
luciferase coding sequence in plasmid pFoxLuc (25). Mutagenesis of the Setd7
gene was performed using the QuickChange Site-Directed Mutagenesis Kit
(Stratagene) according to the manufacturer’s instructions. All sequences were
conﬁrmed by automated DNA sequencing.
Transfections and reporter assays. 10
6 TC3/TC1.6/INS-1 cells or 5  10
5
NIH3T3 cells were seeded in six-well plates 24 h before transfection. Plasmid
(2 g) diluted into 0.1 ml PBS was mixed with 6 l of Metafectene Pro
(Biotex) and incubated at room temperature for 15 min. The transfection
mixture was added to each well of a six-well plate along with 2 ml medium
without antibiotics. At 6 h after transfection, the medium was replaced with
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FIG. 2. Regulation of the mouse Setd7 gene. A: Fragments of the Setd7 promoter in plasmid pFoxLuc1 (pFLO) were transfected into the cell lines
indicated. Luciferase activity was measured 48 h after transfection, corrected for total protein, and normalized to the activity of the promoterless
backbone plasmid. B: An A/T-rich DNA fragment of the Setd7 promoter (5,768 to 6,030) was subcloned into a luciferase reporter plasmid
driven by the prolactin minimal promoter (pFLprl) and transfected into the cell lines indicated. Luciferase activity was normalized to the activity
of pFLprl-transfected cells. C and D: Setd7 gene fragments (wild-type and mutagenized at potential Pdx1 binding sites) were cotransfected with
a cytomegalovirus promoter-driven plasmid (pBAT12) expressing Pdx1 into either TC3 (C) or INS-1 (D) cells. Luciferase activity was
normalized to the activity of cells transfected with the backbone pBAT12 plasmid. Data in all panels represent the average of at least three
independent transfections. E: Results of a ChIP assay using TC3 cell chromatin and either normal rabbit serum (Ab) or primary antibody to
Pdx1 (Pdx1 Ab). Recovery of either the Setd7 or Actb promoters were quantitated by real-time PCR, and data are expressed as fold recovery
compared with the data for normal rabbit serum alone. The ampliﬁed region of the Setd7 gene (in bp) relative to the transcriptional start site
is indicated in parentheses. Data represent the average from three independent ChIP experiments.
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DIABETES, VOL. 58, JANUARY 2009 187fresh medium containing antibiotics. At 48 h after transfection, cells were
harvested and a luciferase assay was performed utilizing a commercially
available luminometric kit (Promega). Luciferase activity was normalized to
protein concentration as measured using the Bio-Rad Protein Assay reagent
(Bio-Rad) according to manufacturer’s instructions.
RESULTS
Set7/9 mRNA and protein are enriched in pancreatic
islets. To evaluate the tissue distribution of Set7/9 in adult
mice, Set7/9 mRNA and protein were assayed in different
tissues by real-time RT-PCR and immunoblot, respectively.
As shown in Fig. 1A, mRNA levels demonstrate a pattern
of tissue-speciﬁc enhancement, with the highest relative
levels seen in muscle, brain, heart, and pancreas. Interest-
ingly, Set7/9 protein levels do not completely mirror Set7/9
mRNA levels (Fig. 1B), as no protein was detectable in
either heart or total pancreas and very little was detectable
in muscle. These data suggest the potential for posttran-
scriptional regulation of Set7/9 expression. However,
within the pancreas, there was clear enrichment of Set7/9
protein within islets as determined by immunoblotting
(Fig. 1B). To directly visualize the distribution of Set7/9
among pancreatic cell types, we next performed immuno-
histochemistry of pancreatic sections from both mice and
humans. Figure 1C and D shows that Set7/9 is strikingly
enriched in islets of mouse pancreas, with a predomi-
nantly nuclear pattern in most cells of the central islet.
Coimmunoﬂuorescence revealed that Set7/9 exhibited a
nuclear pattern in insulin-producing -cells (Fig. 1E–G)
and both a nuclear and cytoplasmic pattern in glucagon-
producing -cells (Fig. 1H–J). All Pdx1-positive cells of the
islet costained for Set7/9 (Fig. 1K–M). Human pancreas
sections demonstrated a Set7/9 staining pattern identical
to that seen in mouse sections (supplemental Fig. S1,
available in an online appendix at http://dx.doi.org/10.
2337/db08-1150).
-Cell–speciﬁc transcription of the Setd7 gene. The
islet-speciﬁc enrichment of Set7/9 suggested the potential
for regulation at the transcriptional level. To explore this
possibility, we placed a range of DNA fragments from the
5 regulatory region of the gene encoding Set7/9 (Setd7)
upstream of the luciferase reporter gene (in plasmid
pFoxLuc [25]). These constructs were then transfected
into the -cell–derived cell lines TC3 and INS-1, the
-cell–derived cell line TC1.6, and the ﬁbroblast-derived
line NIH3T3. As shown in Fig. 2A, -cell lines displayed
enhancement of luciferase activity with a DNA fragment
containing 6,584 bp upstream of the transcriptional start
site. This enhancement was signiﬁcantly attenuated when
a fragment containing 3,131 bp from the transcriptional
start site was used, suggesting the potential for a -cell–
speciﬁc enhancer located between 3,131 and 6,584 bp.
To further explore this possibility, we next performed an
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FIG. 3. Set7/9 is necessary for the expression of a subset of glucose-responsive genes in TC3 cells. TC3 cells were transfected with the siRNAs
indicated, and protein and total RNA were harvested. A: Immunoblots for Set7/9 and actin. B: Quantitative real-time RT-PCR for each of the genes
indicated. Data shown are corrected for Actb mRNA levels and normalized to the levels seen with siControl transfections. Data represent the
average of at least four independent transfections. *Values differ signiﬁcantly (P < 0.05) from those of siControl transfections.
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188 DIABETES, VOL. 58, JANUARY 2009alignment of human, mouse, and rat Setd7 genes to
identify regions of homology that might suggest conserved
-cell–speciﬁc enhancer regions. Although the entire re-
gion between 3,131 and 6,584 bp only exhibited 25%
identity between these species (data not shown), we
identiﬁed a region between 5,768 and 6,030 bp that
exhibited 68% identity (supplemental Fig. S2). Within
this conserved region, we identiﬁed two potential binding
sites for the -cell–speciﬁc transcription factor Pdx1 (con-
sensus: 5-TAAT-3 [refs. 20,26]) (supplemental Fig. S2).
To directly test whether this region of the Setd7 gene
might be regulated in -cells, a DNA fragment containing
this conserved region was placed upstream of the prolac-
tin minimal promoter driving luciferase and used in re-
porter gene analysis studies. As shown in Fig. 2B, this
fragment displayed relative enhancement of luciferase
activity in TC3 and INS-1 -cell lines,but not in NIH3T3
cells. Upon cotransfection with a plasmid encoding Pdx1,
this fragment displayed an 25-fold enhancement in the
-cell lines INS-1 and TC3 (Fig. 2C and D). Mutation of
either putative Pdx1 binding site attenuated activity of this
fragment in both -cell lines (Fig. 2C and D). Pdx1 appears
to occupy the endogenous Setd7 gene in TC3 cells within
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FIG. 5. Set7/9 is necessary for normal islet function. Male C57BL/6J
mice were injected intraperitoneally with stabilized control siRNA or
siRNAs against Set7/9 (siSet1 and siSet2) as described in RESEARCH
DESIGN AND METHODS. Islets were then harvested. A: Islets from injected
mice were subjected to quantitative real-time RT-PCR for each of the
genes indicated. Data shown are corrected for Actb mRNA levels and
normalized to the levels seen with siControl transfections. Data rep-
resent the average of at least four independent transfections. *Values
differ signiﬁcantly (P < 0.05) from those of siControl transfections. B
and C: Islets from injected mice were subjected to GSCa (B) or GSIS
(C) studies at the indicated glucose concentrations. Data in B repre-
sent the average of at least 10 islets pooled from three mice injected
with each siRNA on a single occasion, and data in C represent the
average of 50 islets from six injected mice. Statistical signiﬁcance is
indicated by the P value (from t test) for the comparison with siControl
at 11 mmol/l glucose.
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assay, but does not occupy the endogenous gene encoding
-actin (Fig. 2E). Together, these results suggest that the
Setd7 gene may contain elements that enhance its expres-
sion speciﬁcally in -cells and that the islet transcription
factor Pdx1 may be a necessary component of a transac-
tivation complex on the Setd7 gene.
Set7/9 is necessary for the expression of a subset of
glucose-responsive genes in -cell lines and islets. To
determine the role of Set7/9 in the regulation of -cell–
speciﬁc genes, we next depleted TC3 cells of Set7/9
protein and analyzed gene expression by real-time RT-
PCR. To knock down protein, two different siRNAs (si-
Set97 and siSet98) targeted against murine Set7/9 or
siControl were transfected into TC3 cells. As shown in
Fig. 3A, 	90% reductions in Set7/9 protein were seen
following transfections with each siRNA compared with
those seen in control transfections. Use of two different
siRNAs ensured that any effects on gene transcription
were unlikely a result of off-target effects of these siRNAs.
A survey of islet-speciﬁc genes involved in glucose respon-
siveness showed that the genes encoding the -cell–
speciﬁc transcription factor MafA (MafA), the glucose
transporter Glut2 (Slc2a2), and preproinsulin (Ins1/2)
were reduced signiﬁcantly (Fig. 3B) in cells depleted of
Set7/9. However, reduction was not seen uniformly among
all genes responsible for glucose responsiveness in islets,
as those encoding Pdx1 (Pdx1), the ATP-sensitive K

channel (Kcnj11), sulfonylurea receptors (Abcc8), Nkx6.1
(Nkx6.1), and NeuroD1 (NeuroD1) appeared statistically
unaffected by acute reductions in Set7/9 (Fig. 3B).
To conﬁrm our ﬁndings in primary cells, we next
performed knockdown experiments in mouse islets. How-
ever, a major challenge in RNA intereference studies in
primary rodent islets is their relatively poor transfection
efﬁciency in vitro, which typically necessitates use of
viral-based approaches (27). Instead, we sought to knock
down Set7/9 in islets by delivering chemically stabilized
siRNAs in vivo. A similar technique has been used to target
other proteins for systemic knockdown (28,29). To test the
efﬁcacy of this approach in islets, we performed four daily
intraperitoneal injections of Cy3-labeled double-stranded
RNA into male C57BL/6J mice and subsequently isolated
islets from these animals on day 5. As shown in Fig. 4A,
ﬂuorescent microscopic images of isolated islets revealed
penetration of the Cy3 label into the islets, suggesting islet
entry of siRNA. Two different stabilized siRNAs targeted
against Set7/9 (siSet1 and siSet2) or siControl were then
delivered to mice using the same approach. Following the
injections, islets from mice were then harvested and
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FIG. 6. Set7/9 is necessary for the maintenance of dimethylated H3 Lys4 at speciﬁc genes in TC3 cells. TC3 cells were transfected with the
siRNAs indicated and subjected to ChIP using either normal rabbit serum (Ab) or antibodies to methylated histones. Recovery of the gene
fragments was assessed by real-time PCR. Data are reported as recovery of the indicated gene (Ins1/2 or Slc2a2) following ChIP as a percent of
the input levels of the gene before ChIP. A: Percent recovery of dimethylated H3 Lys4 at the Ins1/2 promoter and coding regions. B: Percent
recovery of momomethylated H3 Lys4 at the Ins1/2 promoter and coding regions. C: Percent recovery of dimethylated H3 Lys4 at the Slc2a2
proximal promoter region. D: Percent recovery of dimethylated H3 Lys4 at the Pdx1 proximal promoter region. Data represent the average of at
least three independent ChIP assays from at least three independent siRNA transfections. *Statistically different (P < 0.05) from data of
siControl transfections. The ampliﬁed region of the genes (in bp) relative to the transcriptional start site is indicated in parentheses below each
gene. f, siControl; , siSet97; o, siSet98.
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GSIS. As shown in Fig. 4B, islet Set7/9 protein was reduced
by at least 60% by treatment with either siRNA compared
with control. Interestingly, similar knockdown was not
observed in liver, brain, or muscle, suggesting that for the
speciﬁc protocol employed, targeting of islets appeared to
be most efﬁcient.
Consistent with the data observed in TC3 cells, deple-
tion of Set7/9 in primary islets resulted in decreases in
MafA, Slc2a2, and Ins1/2 (Fig. 5A). Because decreases in
these genes would be predicted to result in loss of glucose
responsiveness in islets, we tested islet functionality by
GSCa. The GSCa assay is a Fura-2AM dye–based assay
that measures the intracellular mobilization of Ca
2 in
response to glucose and is dependent on an intact signal-
ing cascade that begins with the transport of glucose into
the -cell by GLUT2 and ending in the activation of
voltage-gated Ca
2 channels; intracellular Ca
2 mobiliza-
tion through this cascade is closely linked to insulin
secretion (30). As shown in Fig. 5B, reductions in islet
Set7/9 protein using either siSet1 or siSet2 resulted in
GSCa responses (from 3 to 11 mmol/l glucose) that were
only 50% those associated with control. These islets also
showed diminished GSIS upon raising glucose from 3 to 11
mmol/l (Fig. 5C). Taken together, these results suggest
that Set7/9 is necessary for the transcription of a subset of
islet genes that are required for the maintenance of normal
islet function.
Set7/9 is necessary for the maintenance of H3-Lys4
dimethylation at the Ins1/2 and Slc2a2 genes. In prior
ChIP studies, we demonstrated that Set7/9 occupies the
Ins1/2 genes in TC3 cells (10). This observation, coupled
with the ﬁnding that the Ins1/2 gene is hypermethylated at
H3 Lys4 (10,11), suggested to us that Set7/9 may be
directly responsible for the maintenance of this euchro-
matin histone modiﬁcation at this gene. We therefore
wondered whether the reduction in Ins1/2 gene activity
observed upon knockdown of Set7/9 in this study could be
secondary to loss of H3-Lys4 methylation. As shown in Fig.
6A, depletion of Set7/9 in TC3 cells using either of two
siRNAs (siSet97 or siSet98) led to 50–80% reductions in
dimethylated H3 Lys4 in the Ins1/2 promoter region as
determined by ChIP assay but did not affect dimethylated
H3 Lys4 in the coding region of the gene. Importantly, we
did not observe any changes to monomethylated H3 Lys4
in either the promoter or coding regions of the Ins1/2 gene
(Fig. 6B), suggesting that Set7/9 is associated with a very
speciﬁc dimethylation effect.
To ascertain the speciﬁcity of Set7/9, we next examined
the genes Slc2a2 (whose transcription is reduced by loss
of Set7/9) and Pdx1 (whose transcription is unaffected by
loss of Set7/9). As shown in Fig. 6C and D, we observed a
speciﬁc loss of dimethylated H3 Lys4 at the proximal
Slc2a2 promoter but not at the proximal Pdx1 promoter.
Similar results were obtained in primary mouse islets
depleted of Set7/9 using siSet1, although the decreases in
dimethylated H3 Lys4 at the Ins1/2 and Slc2a2 genes did
not quite approach statistical signiﬁcance (Fig. 7A). These
results are consistent with gene-speciﬁc effects of Set7/9.
To determine whether Set7/9 could be modifying his-
tones directly at the Slc2a2 gene, we next performed ChIP
assays in TC3 cells to assess recruitment of Set7/9 to this
gene. Figure 7B shows that Set7/9 occupies the Slc2a2
gene within its proximal control region (738 to 523 bp
relative to the transcriptional start site) but was not
detected at the proximal Pdx1 promoter. These results
suggest that the chromatin effects observed at the Slc2a2
gene are the result of Set7/9 recruitment to its promoter.
Set7/9 is necessary for the recruitment of RNA poly-
merase II to the Ins1/2 gene. Pdx1, like Set7/9, is
required for the full activation of the Ins1/2 gene
(23,31,32). This effect of Pdx1 is apparently related not to
the recruitment of RNA polymerase II to the Ins1/2 gene
but, rather, to defects in the conversion of RNA polymer-
ase II from its initiation to elongation isoforms (11,23). We
therefore wondered whether the maintenance of Ins1/2
transcription by Set7/9 might be related to Pdx1. As shown
in Fig. 8A, knockdown of Set7/9 in TC3 cells using siSet97
led to no changes in Pdx1 occupancy at the Ins1/2 gene.
However, we observed that RNA polymerase II recruit-
ment to the promoter region of Ins1/2 (and Slc2a2) was
diminished by 50% (Fig. 8B). These results suggest that
Set7/9 action at the Ins1/2 gene may be distinct from that
of Pdx1 and that either Set7/9 itself or its associated
dimethylated H3-Lys4 modiﬁcation is linked to RNA poly-
merase II recruitment.
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FIG. 7. Set7/9 may be necessary for maintenance of dimethylated H3
Lys4 at the Ins1/2 and Slc2a2 genes in mouse islets and occupies the
Slc2a2 gene in TC3 cells. A: Male C57BL/6 mice were injected
intraperitoneally with stabilized control siRNA or siRNA against
Set7/9 (siSet1) as described in RESEARCH DESIGN AND METHODS. Islets were
subsequently harvested and subjected to ChIP using either normal
rabbit serum (Ab) or antibody to dimethylated H3 Lys4 (Ab). Data
are reported as percent recovery of the indicated gene promoter
relative to input. Data represent the average of three independent
ChIP experiments from mice injected on three separate occasions. B:
TC3 cells were subjected to ChIP analysis using normal rabbit serum
(Ab) or antibody against Set7/9 (Set7/9 Ab). Recovery of the proxi-
mal Slc2a2 and Pdx1 promoters are reported as fold recovery relative
to normal rabbit serum. Data represent the average of three indepen-
dent ChIP assays. *Statistically different (P < 0.05) from data of ChIP
assays in which normal rabbit serum was used in place of Set7/9
antibody.
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The islet -cell derives many of its characteristics, partic-
ularly stimulus-secretion coupling, from the transcription
of a unique subset of genes that is controlled by a group of
cell-speciﬁc transcription factors and cofactors. In this
report, we identify a new member of this cohort of
islet-speciﬁc factors, Set7/9, and demonstrate its role in
the maintenance of gene transcription and chromatin
structure in -cell lines and primary islets. Set7/9 was
originally identiﬁed as a histone H3-Lys4–speciﬁc methyl-
transferase (12,13). Subsequently, Set7/9 was shown to
methylate Lys residues in a variety of proteins including
TAF10 (18), TAF7 (17), p53 (14–16), the estrogen receptor
(19), and possibly Pdx1 (11). To date, however, its role in
the maintenance of histone H3–Lys4 methylation at islet
genes has only been implied (11) and not directly studied.
We show that Set7/9 is distributed in a limited number of
tissues in the mouse but includes those derived from all
three major germ layers, including ectoderm (brain), me-
soderm (muscle), and endoderm (pancreas). Within the
pancreas of both the mouse and human, Set7/9 exhibits a
striking islet-speciﬁc distribution pattern. The enrichment
of Set7/9 in -cells may occur at the level of transcription,
as our studies identiﬁed a potential conserved -cell–
speciﬁc enhancer located in the distal Setd7 gene that is
responsive to Pdx1. Its strongly nuclear pattern of distri-
bution, particularly in -cells, suggested to us a role for
Set7/9 in -cell gene regulation.
To identify genes regulated by Set7/9 in -cells, we
engaged RNA interference approaches to knock down
Set7/9 in insulinoma-derived -cells (TC3) and primary
mouse islets. Successful knockdown using multiple differ-
ent siRNAs demonstrated reductions in key genes that
mediate stimulus-secretion coupling, including Slc2a2,
MafA, and Ins1/2. Consistent with these reductions, we
observed impaired GSCa and GSIS in islets depleted of
Set7/9. We note that our knockdown studies were of short
duration by design in order to obtain information on the
most immediate and potentially direct genetic targets of
Set7/9. Thus, we cannot rule out the possibility that other
genes may contribute to the dysfunctional islet phenotype
observed or that more prolonged knockdown may not
have broader effects on islet function, replication, or
survival. Importantly, effects on islet survival are possible,
given that recent studies suggest a role for Set7/9 in the
maintenance of inﬂammatory genes in macrophages (33).
As noted earlier, Set7/9 exhibits speciﬁc methyltrans-
ferase activity toward histone H3 Lys4. Some studies
suggest that it may function as a dimethyltransferase
(341), whereas others suggest that it functions exclusively
as a monomethyltransferase in vitro (35). Although our
data are compatible with the role of Set7/9 as a dimethyl-
transferase in cells, they do not rule out the possibility that
it may indeed function as a monomethyltransferase. For
example, it is possible that Set7/9 is very closely linked to
a second methyltransferase that completes the dimethyla-
tion reaction in cells, such that transient alterations in
monomethylation are not detectable in our system. Alter-
natively, it is possible that catalytic activities observed in
vitro are modiﬁed in the cellular milieu as a result of the
complexity of protein-protein interactions. In this context,
recent studies of the H3-Lys9 methyltransferase G9a show
that it exhibits differing stoichiometries of methylation in
vivo depending on binding to accessory proteins (36).
In the absence of endogenous nuclear localization and
DNA binding domains, we presume that Set7/9 must be
chaperoned to both the nucleus and target genes through
an interaction with transcription factors. We have previ-
ously demonstrated that Set7/9 forms an immunoprecipi-
table complex with Pdx1 (11). In those studies, we also
showed that depletion of Pdx1 in TC3 cells leads to
diminution of H3-Lys4 dimethylation at the Ins1/2
gene—an observation that our present studies suggest
could be caused by disruption of the Pdx1-Set7/9 complex.
Interestingly, however, whereas the depletion of Pdx1 led
to defective conversion of RNA polymerase II to its
elongation isoform (and not its recruitment to the pro-
moter [11,23]), we observed here that depletion of Set7/9
causes impairments in RNA polymerase II recruitment to
the promoter. Our ﬁndings are therefore consistent with
studies suggesting that Set7/9 stabilizes the transcriptional
preinitiation complex by methylation of TAF10 (18).
Taken together, our results suggest a model for Set7/9
action at target -cell genes. We propose that Set7/9 is
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FIG. 8. Loss of Set7/9 affects Pol II but not Pdx1 recruitment. TC3 cells were transfected with siControl or siSet97 and subjected to ChIP using
normal rabbit serum (Ab) or antibody to RNA polymerase II COOH-terminal domain (Ab). Recovery of the gene fragments was assessed by
real-time PCR. Data are reported as recovery of the indicated genes following ChIP as a percent of the input levels of the genes before ChIP. A:
ChIP experiment using antibody to Pdx1. B: ChIP experiment using antibody to RNA polymerase II COOH-terminal domain. Data represent the
average of three independent ChIP assays from three independent siRNA transfections. *Statistically different (P < 0.05) from data of siControl
transfections.
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through interaction with factors such as Pdx1. This re-
cruitment subsequently leads to dimethylation of H3 Lys4
within the promoter region (either directly by Set7/9 or
through interaction with another methyltransferase) and
recruitment of RNA polymerase II. The subsequent con-
version of RNA polymerase II to its elongation isoform
requires other factors that are dependent on Pdx1. The
preponderance of studies in the literature suggest that
dimethylation of H3 Lys4 appears to be crucial for laying a
euchromatic template at target genes, thereby leaving
genes poised for transcription. Although we have demon-
strated an important role for Set7/9 in the transcriptional
regulation of key -cell genes in mature cells, the role of
Set7/9 in establishing transcriptional patterns during the
embryonic development of -cells remains to be deter-
mined. In future studies, we will directly address its role in
embryonic development using conditional Set7/9 knock-
out mice.
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